Notice NOT-CA-24-041 from the NIH Guide for Grants and Contracts

Notice NOT-AI-24-012 from the NIH Guide for Grants and Contracts

Notice NOT-AR-24-013 from the NIH Guide for Grants and Contracts

Notice NOT-AI-24-031 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-RM-24-006 from the NIH Guide for Grants and Contracts. Many valuable and widely available data sets have been generated by multiple Common Fund programs. The purpose of this NOFO is to announce the availability of funding to demonstrate and enhance the utility of selected Common Fund data sets, including generating hypotheses and catalyzing discoveries. Award recipients are also asked to provide feedback on the utility of the Common Fund data resources.

Notice NOT-OD-24-084 from the NIH Guide for Grants and Contracts

Notice NOT-OD-24-086 from the NIH Guide for Grants and Contracts

Notice NOT-OD-24-085 from the NIH Guide for Grants and Contracts

Notice NOT-AG-24-016 from the NIH Guide for Grants and Contracts

Notice NOT-OD-24-093 from the NIH Guide for Grants and Contracts

Notice NOT-DA-24-022 from the NIH Guide for Grants and Contracts

Notice NOT-TR-24-016 from the NIH Guide for Grants and Contracts

Notice NOT-TR-24-017 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-TR-24-023 from the NIH Guide for Grants and Contracts. This notice of funding opportunity (NOFO) provides funding to conduct efficacy studies in an established rare disease preclinical model to demonstrate that a proposed therapeutic agent warrants further development. In addition to preclinical efficacy, accompanying pharmacodynamic and pharmacokinetic studies would be supported. Therapeutic agents include small molecules, biologics or biotechnology-derived products. The goal of this NOFO is to spur therapeutic development for a variety of rare diseases by advancing projects to the point where they would attract subsequent investment supporting full Investigational New Drug (IND) application development or progression to clinical trials in the case of repurposing or repositioning.

Funding Opportunity RFA-DK-25-009 from the NIH Guide for Grants and Contracts. This NOFO encourages applications from institutions that propose to establish research experiences in kidney technology development. Successful programs should include a collaborative capstone research or design project(s), innovative and/or ground-breaking technology development, multidisciplinary/interdisciplinary teamwork, education in entrepreneurship, product development and navigating regulatory pathways, and clinical immersion. The intent of this NOFO is to recruit undergraduate students as participants and to engage students from engineering and technical domains, but applicants may also propose the inclusion of medical students, graduate students and/or dual-degree students (e.g., M.D./Ph.D.; Pharm.D./Ph.D.) prior to their qualifying exams and selection of Ph.D. mentor.

Funding Opportunity RFA-MH-25-190 from the NIH Guide for Grants and Contracts. The purpose of this phased Notice of Funding Opportunity (NOFO) is to create a pipeline to accelerate the development and early validation of predictive tools and/or biomarkers to inform individual-level treatment selection among two or more existing therapeutics for depression. This phased inter-agency program will be milestone-based and provide support from multi-disciplinary teams to address scientific, technical, clinical, regulatory, and commercialization requirements. In the first phase (UG3), investigators are expected to identify potential tools and/or biomarker(s) that can predict whether a patient will differentially respond to one well-established depression treatment versus another. This could be accomplished using secondary analysis of data from completed clinical trials or using real-world clinical data, or by conducting small, efficient pilot feasibility studies to assess promising new tools or biomarkers to predict individual treatment response to a specific therapeutic for depression. In the second phase (UH3), investigators will conduct independent, prospective clinical trials to initially validate the utility of the tool/biomarker for predicting differential response to established treatments for depression. The overall goal of this NOFO is to support the testing of various tools/biomarkers as predictors of response to well-established depression treatments and halt the development of those tools that do not meet sufficient performance characteristics to justify further testing. Ultimately, tools that are successful in early-stage studies could be further evaluated for future use in decision-making in clinical practice settings.

Notice NOT-TW-24-004 from the NIH Guide for Grants and Contracts

Notice NOT-AG-24-015 from the NIH Guide for Grants and Contracts

Notice NOT-HD-24-019 from the NIH Guide for Grants and Contracts

Notice NOT-HD-24-020 from the NIH Guide for Grants and Contracts